search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
The latest Business updates from the science industry


by Heather Hobbs Grant to Back Blood Cell Substitute Research


The funding, awarded by Innovate UK will extend over two years to March 2019, with research at Edinburgh being led by Lesley Forrester, Professor of Stem Cell Differentiation, at the MRC Centre for Regenerative Medicine.


Over 90 million blood transfusions are carried out worldwide each year and alternative sources to donor-derived blood are being sought to meet rising demand. In addition there is a need to secure a safer supply of blood products, chiefl y in developing countries where there is a relatively higher risk of transfusion-transmitted infection, but also globally where supply chains solely reliant on human donors remain vulnerable to newly emerging diseases.


“Scientists have shown that pluripotent stem cells can be used to make red blood cells in the laboratory, however as is often the case with stem cell – derived products, the process is costly, ineffi cient and gives rise to many immature cells, preventing the therapy from progressing to clinical trials,” commented Dr Yen Choo, Executive Chairman of Plasticell. “We will use CombiCult® – Plasticell’s combinatorial stem cell screening technology – to greatly improve the manufacturing process, focusing particularly on the early stages of stem cell differentiation into hematopoietic progenitors that give rise to fully functional red blood cells.”


Dr Yen Choo


A Biomedical Catalyst funding of over £920,000 is to support collaborative research between cell therapies developer Plasticell and stem cell scientists at the University of Edinburgh, aiming to create a safe, effective red blood cell substitute for human clinical transfusion.


The project is part of Plasticell’s hematopoietic cell therapy portfolio, which includes the expansion of umbilical cord- and bone- derived hematopoietic stem cells, and the manufacture of blood platelets and immune cells for oncology applications.


42609pr@reply-direct.com


Ingenza Welcomes Japanese Trade Delegation to Scotland


Ingenza is pleased to announce that it will be hosting representatives of the Japanese government, academic and technology sectors later this month. The Japanese Ministry of Economy, Trade and Industry (METI) delegation will visit the company’s Roslin BioCentre site as part of a mission to learn more about the UK’s rapidly expanding biotechnology industry.


The delegation includes members of METI and the New Energy and Industrial Technology Development Organisation (NEDO), as well as representatives of leading industrial and academic organisations – and aims to understand how the UK’s bioeconomy strategy is translating research advances into commercially successful enterprises. Synthetic


biology is playing a key role in this success, and the group has asked to visit Ingenza to learn more about the company’s technologies and activities.


Dr Ian Fotheringham, Managing Director of Ingenza, commented: “We are delighted to have been asked to host a visit from this delegation. The UK bioeconomy is one of the strongest in the world, and growing rapidly, and it is a real honour to have been singled out for our contribution to this growing sector.”


42483pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154  |  Page 155  |  Page 156  |  Page 157  |  Page 158  |  Page 159  |  Page 160  |  Page 161  |  Page 162  |  Page 163  |  Page 164  |  Page 165  |  Page 166  |  Page 167  |  Page 168  |  Page 169  |  Page 170  |  Page 171  |  Page 172